Notice of Correction to PAR-19-223, "Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)"

Notice Number: NOT-DA-19-031

Key Dates
Release Date: April 12, 2019

Related Announcements

PAR-19-223

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The purpose of the Notice is to correct the Letters of Reference in PAR-19-223, "Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)".

Currently Reads:

Section IV. Application and Submission Information

7. Other Submission Requirements and Information

Instructions for Referees:

Letters may be submitted to the Commons at

(https://public.era.nih.gov/commons/public/reference/submitReferenceLetter.do?mode=new) beginning September 20 and must be submitted no later than 5:00 p.m. (local time of applicant organization), October 20. Late letters will not be accepted and applications with fewer than three letters will not be reviewed. Letters must be submitted electronically – paper copies will not be accepted.

Modified to Read:

Section IV. Application and Submission Information

7. Other Submission Requirements and Information

Instructions for Referees:

Letters may be submitted to the Commons at

(https://public.era.nih.gov/commons/public/reference/submitReferenceLetter.do?mode=new) Letters may be submitted beginning September 21, 2019 and must be submitted no later than 5:00 p.m. (local time of applicant organization), October 21, 2019 for application receipt date of October 21, 2019. For application receipt date of October 19, 2020 letters may be submitted September 19, 2020 and must be submitted no later than 5:00 p.m. (local time of applicant organization) on October 19, 2020. For application receipt date of October 18, 2021 letters may be submitted September 18, 2021 and must be submitted no later than 5:00 p.m. (local time of applicant organization) on October 18, 2021. Late letters will not be accepted and applications with fewer than three letters will not be reviewed. Letters must be submitted electronically – paper copies will not be accepted.

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Jonathan D. Pollock, Ph.D.
National Institute on Drug Abuse
Telephone: 301-435-1309
Email:jpollock@mail.nih.gov